A comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Tomokazu Ichikawa

Director, TM Research and Investments Pte. Ltd.

Leveraged cross-functional expertise in business strategy and legal to work on strategy development, M&A, and investments in the medical device sector. Practiced law at Nagashima, Ohno and Tsunematsu, handling M&A and other corporate matters. Worked for McKinsey & Company and Hoya Corporation. Completed several acquisitions and investments in the US and Europe in the medical device business. Experienced managing a healthcare service operator in India. Currently, helping AI Medical Service, an artificial intelligence software startup for endoscope and CUC, a healthcare service provision related company. Spent more than 10 years in Singapore and familiar with business in Southeast Asian countries. Graduated from Waseda University, London Business School's Masters in Finance, and Cambridge's MBA. Attorney at law admitted in Japan.

Yoshiki Kawabata

President, MedX Inc.

Advantage from over 35 years of multiple company & responsibility experience in medical device industry, helping foreign companies to enter into Japanese market. Key highlights in the past achievements are : with Johnson & Johnson Mdecial Company, worked with US R&D team to develop new product which reflecting Japanese patient and physicians needs - three years resided in Cincinnati, Ohio: HeartFlow Inc., which developed the first "program device" - FFRCT, enabling non-invasive detection of FFR, applied and received regulatory approval and reimbursement as a first product and company. : in Palette Lifesciences Japan, establishment of new subsidiary for start-up company which transferred the business from exclusive distributor. Started with minimum number of direct resources and having multiple partnerships with logistics, finance and regulatory affairs, revitalized the business and achieved a 149% growth over the last year of distributor.

Tadashi Sameshima

I have been engaged in product development and business operations of medical devices and regenerative medicine products for 37 years at Terumo Corporation. I have experienced the development of medical devices such as extracorporeal circulatory and blood transfusion devices, as well as the development to commercialization of cellular products. In addition, I am able to provide specific advice on various stages of development based on my participation in joint research with universities, collaboration among companies, discussions with government agencies, and activities of industry associations.

Ruka Takeuchi

Discovery Biotech Consulting　　Representative
PARKS　Commercialization Producer

I have been engaged in marketing and business development for more than 30 years in the life science market, mainly in the medical and pharmaceutical fields, both in Japan and overseas. Currently, I have established my own consulting firm and provide business consulting services to foreign and domestic companies from start-ups to small and medium-sized enterprises. I would be happy to be of service to you by drawing on my past business experience as well as my daily experience in providing hands-on support to various companies and projects.

Tomoko Maeda-Chubachi

TMC Clinical Development Consulting, Inc, President; The Institute of Drug Development Career Promotion, Founding Director; Japan Alliance of Medical School Startups, Director

Dr. Maeda-Chubachi is an advisor and consultant for pharmaceutical and biotech companies and was the Chief Medical Officer at Pelthos Therapeutics (previously Novan), leading First-in-Human to launch preparation. Tomoko is known for her expertise in drug development with over 20 years industry experience. She has led clinical and medical affairs in large pharma as well as a small biotech. She led global drug development teams, resulting in 8 approvals in multiple regions, including Xalatan, Xeljanz, Taltz, Vtama, and Zelsuvmi.　Tomoko has broad knowledge of drug development, of which process is highly regulated and need thorough risk assessment, management, and control. As a Chief Medical Officer, she worked closely with the CEO and board about the strategy and governance.